New pill aims to tackle obesity: early trial tests how the body handles the drug

NCT ID NCT05841238

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This early-stage study tests an experimental oral drug called LY3502970 in healthy adults who are overweight or obese. The main goal is to see how the drug enters the bloodstream and how the body clears it, as well as to check for any safety issues. Participants will take the drug in tablet or capsule form, and the study also looks at how food affects the drug. Results will help decide whether to move forward with larger trials for weight management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3502970 (oral drug)
What this could lead to: If successful, this could lead to a new oral medication for weight management in people who are overweight or obese.
What could go wrong: This is a very early (Phase 1) study focused on safety and drug levels, not weight loss. The drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OBESE

Contacts and locations

Show contact details

Locations

LabCorp CRU, Inc.

Daytona Beach, Florida, 32117, United States
LabCorp CRU, Inc.

Madison, Wisconsin, 53704, United States
Labcorp Clinical Research LP

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.